The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Syma Iqbal, MD
Advertisement
Articles by Syma Iqbal, MD
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of gastric cancer.
Advertisement
Latest Updated Articles
- Gastric Cancer
Published: June 1st 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
